Clinical Trial Update: Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial is evaluating a Fluorine-18 labeled AlphaVbeta6-binding peptide as a PET imaging agent for metastatic non-small cell lung cancer and is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Fluorine-18-AlphaVbeta6-Binding Peptide (Fluorine-18 labeled AlphaVbeta6-binding peptide)

Snippet

Sponsor: University of California, Davis | Conditions: Lung Cancer, Lung Cancer Metastatic | Phase 1 | Status: RECRUITING